直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

Deadline Evolution: Director Extends Deadline for Requesting Director Review of Institution Grants to 30 Days

June 30, 2026

Authored and Edited by Annabeth R. Foley; Forrest A. Jones; Safiya Aguilar

In Light & Wonder, Inc., v. Evolution Malta, Ltd., IPR2025-01072, Paper 30 (Director June 22, 2026) (precedential), the Director invoked his authority under 37 C.F.R. § 42.5(b) to waive the 14-day time period for requesting Director Review of decisions granting institution. The waiver extends the timeline to thirty days and applies to all cases “moving forward”—meaning parties now have the same time to request Director Review of grants of institution , denials of institution, and final decisions alike.

The determination to waive the 14-day deadline arose after considering the “unique procedural posture” of the Light & Wonder IPR proceedings and the parallel litigation involving the same parties. There, the district court granted Petitioner’s motion to dismiss the litigation with prejudice, after finding that the challenged claims were directed to patent ineligible subject matter under 35 U.S.C. § 101. The district court’s decision issued after the Board instituted IPRs and after the deadline for requesting Director Review passed. And although Patent Owner moved to terminate the IPRs based on the district court’s finding of invalidity, the Board did not have authority to grant such a request.

“Recogniz[ing] that changed circumstances can surface after the deadline to file a request for Director Review has elapsed but before trial has progressed meaningfully” and that initiating sua sponte review “is not always the most efficient process,” the Director resolved to extend the deadline for requesting director review to 30 days “moving forward.”

The Director further explained that the Office may extend the deadline for requesting Director Review of an institution decision in “exceptional circumstances,” so long as the “trial has not progressed meaningfully.” Examples of exceptional circumstances include the dismissal of all, or substantially all claims in a co-pending litigation, findings of fact and conclusions of law that render all or substantially all challenged claims invalid, or a violation of a Sotera stipulation.

Finally, the Director concluded that termination of the Light & Wonder IPR proceedings was appropriate under Hulu. Because all of the challenged claims had been found invalid and trial had not meaningfully progressed, the Director found that “it is unnecessary and inefficient to maintain these IPRs.”

Tags

discretionary denials, motion to dismiss, 35 U.S.C. § 101

Related Practices

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Related Industries

Communications

Media

Related Offices

Washington, DC

Contacts

Annabeth R. Foley
Associate
Washington, DC
+1 202 408 4031
Email
Forrest A. Jones
Partner
Washington, DC
+1 202 408 4019
Email
Safiya Aguilar
Associate
Washington, DC
+1 202 408 4160
Email

Copyright © 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Conference

Patent Litigation Europe 2027

January 18-20, 2027

Amsterdam

Conference

IP Life Sciences Forum 2026

December 13-15, 2026

Coral Gables

Seminar

Global Patent Strategies for Life Sciences and Chemical Innovations: Key Developments in Europe and the United States – Osaka

December 10, 2026

Osaka

Seminar

Global Patent Strategies for Life Sciences and Chemical Innovations: Key Developments in Europe and the United States – Tokyo

December 8, 2026

Tokyo

Conference

WTR Live: Brand Strategy Summit Asia 2026

December 2-3, 2026

Pickering

Webinar

Texas Patent Practice 2026: Essential Strategies for European Technology Companies

December 1, 2026

Webinar

Webinar

Data and Market Exclusivity: An Update on China’s New Law and Comparisons to the US and Europe

November 19, 2026

Webinar

Workshop

From Innovation to Commercialization: U.S. Patent Strategies, Licensing, and IP Transaction Best Practices

November 17, 2026

Beijing

Charitable

2026 ALYN Hospital Wheels of Love Ride

November 8-12, 2026

Northern District

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP